M
IKT icon

Murchinson’s Inhibikase Therapeutics IKT Stock Holding History

Murchinson’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-36,825
Closed -$327K – 122
2021
Q4 		$327K Sell
36,825
-16,666
-31% -$184K 0.03% 75
2021
Q3 		$610K Hold
53,491
– – 0.3% 37
2021
Q2 		$899K Buy
+53,491
New +$1.57M 0.32% 49

Other funds holding IKT

ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
KC
Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HLA
Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $401M AUM 14.95% 1-Year Est. Return
LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return

Murchinson's IKT Position: Q1 2022 in Review

Murchinson sold out of Inhibikase Therapeutics (IKT) in Q1 2022, closing a stake of 36,825 shares — an estimated $327K sold.

Murchinson first reported a position in IKT in Q2 2021 and held it in 3 quarters. The position peaked at $899K in Q2 2021. 24 funds tracked by Wall St. Rank hold IKT as of Q1 2022.

  • Murchinson reported no remaining Inhibikase Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Murchinson sold 36,825 Inhibikase Therapeutics shares in Q1 2022, an estimated $327K.
  • Murchinson first reported a position in Inhibikase Therapeutics in Q2 2021 and held it in 3 quarters.
  • Murchinson's Inhibikase Therapeutics position peaked at $899K in Q2 2021.
  • 24 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2022.

Based on Murchinson's 13F filing for Q1 2022, filed 12 May 2022.